Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 19/20 | 0.66 |
| ▸ | SMO | Q99835 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16300041 | 0.88 | NR3C1 (0.49) | NR3C1SMOPGR | |
| SCHEMBL3590267 | 0.81 | NR3C1 (0.67) | NR3C1SMO | |
| SCHEMBL1362907 | 0.81 | NR3C1 (0.82) | NR3C1 | |
| SCHEMBL27724614 | 0.80 | NR3C1 (0.81) | NR3C1PGR | |
| SCHEMBL1364062 | 0.80 | NR3C1 (0.68) | NR3C1SMO | |
| SCHEMBL3602080 | 0.79 | NR3C1 (0.57) | NR3C1SMO | |
| SCHEMBL9913433 | 0.78 | TRPA1 (0.40) | NR3C1 | |
| SCHEMBL4761721 | 0.78 | NR3C1 (0.77) | NR3C1PGR | |
| SCHEMBL28769262 | 0.78 | NR3C1 (0.69) | NR3C1SMOPGR | |
| SCHEMBL3585078 | 0.77 | NR3C1 (0.55) | NR3C1SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198311-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100075961-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
| EP-2099767-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF- B ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008057857-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075961-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NR0B1, NFKB2 | NR3C1 5/4885SMO 1265/4885PGR 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.